The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Frederick LockeDuring the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Frederick Locke, Moffitt Cancer Center, Tampa, US. We asked, Is ALLO-501A a promising alternative to autologous CAR T-cells?
ALPHA2: Is ALLO-501A a promising alternative to autologous CAR T-cells?
ALLO-501A is an off-the-shelf, anti-CD19 allogeneic CAR T-cell therapy which is gene edited to disrupt the TCRα gene to reduce GvHD risk, as well as the CD52 gene to allow the use of ALLO-647, an anti-CD52 mAb, for lymphodepletion without affecting grafted CAR T-cells. Locke evaluates safety and efficacy results from the phase II ALPHA2 trial, investigating ALLO-647 in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).